Literature DB >> 17698570

Antibody-independent, CD4+ T-cell-dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteins.

Alan Basset1, Claudette M Thompson, Susan K Hollingshead, David E Briles, Edwin W Ades, Marc Lipsitch, Richard Malley.   

Abstract

Immunity to pneumococcal colonization in mice by exposure to live or killed pneumococci has been shown to be antibody independent but dependent on CD4+ T cells. Here we show that intranasal immunization with pneumococcal proteins (pneumococcal surface protein C, adhesin A, and a pneumolysoid) can elicit a similar mechanism of protection. Colonization could be significantly reduced in mice congenitally deficient in immunoglobulins after intranasal immunization with this mixture of proteins; conversely, the depletion of CD4+ T cells in immunized wild-type mice at the time of challenge eliminated the protection afforded by immunization. Overall, our results show that intranasal immunization with a mixture of pneumococcal proteins protects against colonization in an antibody-independent, CD4+ T-cell-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17698570      PMCID: PMC2168310          DOI: 10.1128/IAI.00773-07

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  24 in total

1.  Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae.

Authors:  D E Briles; E Ades; J C Paton; J S Sampson; G M Carlone; R C Huebner; A Virolainen; E Swiatlo; S K Hollingshead
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci.

Authors:  R Malley; M Lipsitch; A Stack; R Saladino; G Fleisher; S Pelton; C Thompson; D Briles; P Anderson
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

Review 3.  The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae.

Authors:  D E Briles; S K Hollingshead; G S Nabors; J C Paton; A Brooks-Walter
Journal:  Vaccine       Date:  2000-12-08       Impact factor: 3.641

4.  Some aspects of the pneumococcal carrier state.

Authors:  R Austrian
Journal:  J Antimicrob Chemother       Date:  1986-07       Impact factor: 5.790

5.  Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection.

Authors:  B P Arulanandam; J M Lynch; D E Briles; S Hollingshead; D W Metzger
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

6.  Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae.

Authors:  Priya Balachandran; Alexis Brooks-Walter; Anni Virolainen-Julkunen; Susan K Hollingshead; David E Briles
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

7.  Low CD4 T cell immunity to pneumolysin is associated with nasopharyngeal carriage of pneumococci in children.

Authors:  Qibo Zhang; Linda Bagrade; Jolanta Bernatoniene; Ed Clarke; James C Paton; Tim J Mitchell; Desmond A Nunez; Adam Finn
Journal:  J Infect Dis       Date:  2007-03-06       Impact factor: 5.226

8.  A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene.

Authors:  D Kitamura; J Roes; R Kühn; K Rajewsky
Journal:  Nature       Date:  1991-04-04       Impact factor: 49.962

9.  Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae.

Authors:  David E Briles; Susan K Hollingshead; James C Paton; Edwin W Ades; Lea Novak; Frederik W van Ginkel; William H Benjamin
Journal:  J Infect Dis       Date:  2003-07-14       Impact factor: 5.226

10.  Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection.

Authors:  Richard Malley; Philipp Henneke; Sarah C Morse; Michael J Cieslewicz; Marc Lipsitch; Claudette M Thompson; Evelyn Kurt-Jones; James C Paton; Michael R Wessels; Douglas T Golenbock
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-04       Impact factor: 11.205

View more
  39 in total

1.  Intranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen a protects mice against nasopharyngeal colonization by Streptococcus pneumoniae.

Authors:  Jianghong Xu; Wenjia Dai; Zhengmin Wang; Bing Chen; Zhongming Li; Xiaoyong Fan
Journal:  Clin Vaccine Immunol       Date:  2010-11-03

2.  Mechanisms in the serotype-independent pneumococcal immunity induced in mice by intranasal vaccination with the cell wall polysaccharide.

Authors:  Ying-Jie Lu; Ian Chr Skovsted; Claudette M Thompson; Porter W Anderson; Richard Malley
Journal:  Microb Pathog       Date:  2009-07-03       Impact factor: 3.738

3.  Genetic diversity of the Pneumococcal CbpA: Implications for next-generation vaccine development.

Authors:  Muna F Abry; Kelvin M Kimenyi; Fred O Osowo; Willingtone O Odhiambo; Steven O Sewe; Benard W Kulohoma
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Timing of Toll-like receptor 9 agonist administration in pneumococcal vaccination impacts both humoral and cellular immune responses as well as nasopharyngeal colonization in mice.

Authors:  Katrine M Jensen; Jesper Melchjorsen; Frederik Dagnaes-Hansen; Uffe B S Sørensen; Rune R Laursen; Lars Østergaard; Ole S Søgaard; Martin Tolstrup
Journal:  Infect Immun       Date:  2012-02-27       Impact factor: 3.441

5.  Characterization of Th17 responses to Streptococcus pneumoniae in humans: comparisons between adults and children in a developed and a developing country.

Authors:  Anna Lundgren; Taufiqur R Bhuiyan; Daniel Novak; Joanna Kaim; Adi Reske; Ying-Jie Lu; Firdausi Qadri; Richard Malley
Journal:  Vaccine       Date:  2012-04-12       Impact factor: 3.641

6.  CD8+ cells enhance resistance to pulmonary serotype 3 Streptococcus pneumoniae infection in mice.

Authors:  Sarah E Weber; Haijun Tian; Liise-anne Pirofski
Journal:  J Immunol       Date:  2010-12-06       Impact factor: 5.422

7.  Nasopharyngeal Exposure to Streptococcus pneumoniae Induces Extended Age-Dependent Protection against Pulmonary Infection Mediated by Antibodies and CD138+ Cells.

Authors:  Elsa N Bou Ghanem; Nang H Tin Maung; Nalat Siwapornchai; Aaron E Goodwin; Stacie Clark; Ernesto J Muñoz-Elías; Andrew Camilli; Rachel M Gerstein; John M Leong
Journal:  J Immunol       Date:  2018-04-16       Impact factor: 5.422

8.  Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice.

Authors:  Maria Leonor S Oliveira; Eliane N Miyaji; Daniela M Ferreira; Adriana T Moreno; Patricia C D Ferreira; Fernanda A Lima; Fernanda L Santos; Maria Aparecida Sakauchi; Célia S Takata; Hisako G Higashi; Isaías Raw; Flavia S Kubrusly; Paulo L Ho
Journal:  PLoS One       Date:  2010-05-27       Impact factor: 3.240

9.  Characterization of protective mucosal and systemic immune responses elicited by pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice.

Authors:  D M Ferreira; M Darrieux; D A Silva; L C C Leite; J M C Ferreira; P L Ho; E N Miyaji; M L S Oliveira
Journal:  Clin Vaccine Immunol       Date:  2009-03-11

10.  Differential requirements for protection against mucosal challenge with Francisella tularensis in the presence versus absence of cholera toxin B and inactivated F. tularensis.

Authors:  Constantine Bitsaktsis; Deepak B Rawool; Ying Li; Nitin V Kurkure; Bibiana Iglesias; Edmund J Gosselin
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.